Celator Pharmaceuticals Inc., of Ewing, N.J., said it achieved 75 percent enrollment in its ongoing phase III trial comparing CPX-351 (cytarabine;daunorubicin) liposome injection vs. the conventional cytarabine and daunorubicin treatment regimen as first-line therapy in older patients with high-risk acute myeloid leukemia.